Effect of a CCK-1R [cholecystokinin 1 receptor] agonist [GW 181771] on food intake in humans.
Phase of Trial: Phase II
Latest Information Update: 02 May 2017
At a glance
- Drugs GW 181771 (Primary)
- Indications Bulimia nervosa; Obesity
- Focus Therapeutic Use
- 26 Apr 2017 Status changed from completed to discontinued.
- 10 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Mar 2010 Actual number of patients added to 40 as reported by ClinicalTrials.gov.